COLL

Business Context and Reporting Period

Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2015
Business Overview: A specialty pharmaceutical company developing abuse-deterrent products using its DETERx platform. The lead product candidate, Xtampza ER (oxycodone), received Fast Track status from the FDA. The New Drug Application (NDA) was accepted by the FDA on February 10, 2015, with a PDUFA goal date of October 12, 2015. The company has no approved products and has not generated revenue since 2011.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported a basic EPS of $0.34 for Q1 2015 due to a significant non-cash gain on the extinguishment of preferred stock, while diluted EPS was $(0.65).

Material Changes vs. Prior Period

• Liquidity Surge: Cash and cash equivalents increased from $1.6 million at December 31, 2014, to $45.0 million at March 31, 2015. This was driven by the issuance of Series D convertible preferred stock.
• Financing Activity: In March 2015, the company raised $50.0 million in aggregate consideration (including $45.0 million cash) via Series D preferred stock. Additionally, $5.0 million in convertible bridge notes with related parties converted into Series D stock.
• Expense Shifts:
  • R&D Expenses: Decreased by $1.8 million to $1.4 million, primarily due to the completion of clinical trials for Xtampza in 2014.
  • G&A Expenses: Increased by $1.7 million to $2.2 million, driven by higher professional fees (audit/accounting), salaries, commercialization consulting, and legal fees related to litigation.
• Balance Sheet: Total assets grew from $5.1 million to $47.4 million. Total liabilities decreased from $17.3 million to $12.9 million, largely due to the conversion of bridge notes and preferred stock accretion adjustments.

Guidance, Outlook, and Risks

Outlook and Subsequent Events:

• IPO: In May 2015 (subsequent to the reporting period), the company closed an Initial Public Offering (IPO), selling 6.67 million shares at $12.00 per share for net proceeds of approximately $71.8 million.
• Runway: Management believes existing cash resources combined with IPO proceeds will fund operations into mid-2017, covering commercialization of Xtampza (if approved) and further development.
• Profitability: The company expects to continue incurring net losses in the foreseeable future as it scales commercialization and R&D.

Risks and Contingencies:

• Patent Litigation: Purdue Pharma, L.P. sued Collegium in March 2015 in the District of Delaware and Massachusetts, asserting infringement of four patents related to OxyContin OP. This litigation could trigger a 30-month stay on FDA approval for Xtampza.
• Regulatory Approval: Success depends on FDA approval of the NDA. The company faces risks regarding the outcome of clinical trials and regulatory reviews.
• Capital Needs: The company may require additional funding beyond current resources. Failure to raise capital could force delays or discontinuation of product development.

Investor Verification Checklist

• IP Litigation Status: Verify the current status of the patent infringement lawsuits filed by Purdue Pharma and the potential impact on the 30-month FDA stay.
• IPO Proceeds Utilization: Confirm the actual use of the $71.8 million net IPO proceeds and whether the mid-2017 cash runway estimate remains valid.
• Regulatory Timeline: Monitor the FDA review process for Xtampza ER against the October 12, 2015, PDUFA goal date.
• Commercialization Costs: Assess the accuracy of projected expenses for building a sales force of ~100 representatives and detailing to 10,000 physicians.
• Preferred Stock Conversion: Confirm the terms and timing of the automatic conversion of all preferred stock series to common stock following the IPO.